US drug-maker Merck’s [MRK] share price jumped to a 52-week high when the company announced an antiviral drug that has the potential to halve the chances of dying from or being hospitalised by COVID-19 on October 4.
“We will continue to work with regulatory agencies on our applications and do everything we can to bring molnupiravir to patients as quickly as possible,” said Robert M Davis, chief executive officer and president, Merck.
It is yet to receive approval from the US Food and Drug Administration (FDA).
The drug, molnupiravir is the first oral medication for COVID-19. It is designed to introduce errors into the genetic code of the virus. It corrupts the virus, preventing multiplication of its cells. As a result, the virus’s ability to attack the body’s immune system is weakened and the body can fight it more effectively.
The Merck news was a bitter pill for the Moderna [MRNA] share price — it tumbled when trading opened the week commencing 4 October. Although up 191.9% year-to-date, the Moderna share price was down 10.6% in the weekdays to October 11. It also sparked a selloff of vaccine stocks in Asia, tanking Shanghai Fosun Pharmaceutical Group Co [SHA: 600196], which distributes the vaccine developed by Pfizer [PFE] and BioNTech [BNTX] throughout China.
Conversely, shares of Atea Pharmaceuticals [AVIR] soared in reaction to Merck’s positive data. The company is collaborating with Roche [0QQ6.L] to develop its own oral COVID-19 treatment — research is ongoing.
Research Journey
Former FDA commissioner Scott Gottlieb is excited by the breakthrough. In an interview with CNBC, he described it as a “profound game changer”.
Merck bought the worldwide rights to molnupiravir from Ridgeback, who licensed the drug from researchers at Emory University in 2020. Gottlieb praised Ridgeback’s Wayne Holman and Wendy Holman as a “very good drug-hunting team”. They previously developed the only FDA-approved, single-injection Ebola treatment, Ebanga.
Findings from the molnupiravir trials show that it can halve mortality among hospitalised, unvaccinated people.
Gottlieb expects molnupiravir to receive approval, given its strong safety profile. He also envisages molnupiravir being used alongside Regeneron’s antiviral treatment. The former can be taken at home twice a day for five days. And if a person does have to be admitted to hospital, they could be treated with the latter.
Order pipeline for Merck
In June, the US signed a $1.2bn deal for 1.7mn courses of molnupiravir. A number of Asia-Pacific countries are rushing to get their hands on the antiviral pill as well. Both Singapore and Australia have signed agreements with Merck. Thailand has joined the mix as well.
The fact that molnupiravir can be taken at home and does not need to be refrigerated means it could be an effective treatment for people in remote and rural areas.
$1.2billion
Amount US spent on 1.7 million courses of molnupiravir in June
Though molnupiravir could reduce mortality and the number of cases of severe illness, vaccination rollouts will remain critical to life returning to pre-pandemic normality.
Mara Goldstein, an analyst with Mizuho Securities, believes molnupiravir has the potential to be worth between $1bn and $10bn to Merck, reported Bloomberg.
Disclaimer Past performance is not a reliable indicator of future results.
CMC Markets is an execution-only service provider. The material (whether or not it states any opinions) is for general information purposes only, and does not take into account your personal circumstances or objectives. Nothing in this material is (or should be considered to be) financial, investment or other advice on which reliance should be placed. No opinion given in the material constitutes a recommendation by CMC Markets or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person.
The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although we are not specifically prevented from dealing before providing this material, we do not seek to take advantage of the material prior to its dissemination.
CMC Markets does not endorse or offer opinion on the trading strategies used by the author. Their trading strategies do not guarantee any return and CMC Markets shall not be held responsible for any loss that you may incur, either directly or indirectly, arising from any investment based on any information contained herein.
*Tax treatment depends on individual circumstances and can change or may differ in a jurisdiction other than the UK.
Continue reading for FREE
- Includes free newsletter updates, unsubscribe anytime. Privacy policy
